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Introduction: Although genetic variants of the A disintegrin and metalloproteinase 10 (ADAM10) gene have been
shown to be associated with susceptibility to several inflammatory-related diseases, to date little is known about
the clinical relationship in the development of sepsis.
Methods: Two genetic variants in the promoter of ADAM10 were selected to analyze the potential association with
the risk of sepsis. A total of 440 sepsis patients and 450 matched healthy individuals in two independent Chinese
Han population were enrolled. Pyrosequencing and polymerase chain reaction-length polymorphism was used to
determine the genotypes of the rs514049 and rs653765. A real-time qPCR method was used to detect the mRNA
level of ADAM10. Enzyme-linked immunosorbent assay was used to measure the expression levels of substrates
CX3CL1, interleukin (IL)-6R, tumor necrosis factor alpha (TNF-α), and the pro-inflammatory cytokines IL-1β and IL-6.
Luciferase assay was used to analyze the activities of the promoter haplotypes of ADAM10.
Results: No statistically significant differences between sepsis cases and controls in the genotype or allele frequencies
were observed, suggesting that ADAM10 single nucleotide polymorphisms (SNPs) may not be risk factors for the
occurrence of sepsis. A significant difference in the genotype and allele frequencies of the rs653765 SNP between
patients with sepsis subtype and severe sepsis (P = 0.0014) or severe sepsis/sepsis shock (P = 0.0037) were observed.
Moreover, the rs653765 CC genotype in severe sepsis showed a higher ADAM10 level compared to healthy groups,
and the rs653765 CC polymorphism had a strong impact on the production of the ADAM10 substrates CX3CL1, IL-6R
and TNF-α. Furthermore, the functional assay showed that ADAM10 C-A haplotype carriers exhibited significantly higher
reporter activity compared with the T-A carriers and T-C carriers in human acute monocytic leukemia cell line.
Conclusions: Our data initially indicated the ADAM10 rs653765 polymorphism was associated with the development
of severe sepsis; the risk CC genotype could functionally affect the expression level of ADAM10 mRNA and was
accompanied by the up-regulation of its substrates. Thus, ADAM10 might be clinically important and play a critical role
in the pathogenesis of the development of sepsis, with potentially important therapeutic implications.* Correspondence: yimingshao_gmc@126.com; keshenli1971@126.com
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Table 1 Demographic characteristics of sepsis patients
and healthy controls





Age, years, mean ± SD 62.9 ± 18.5 62.0 ± 14.7 0.661
Gender, male/female, number 200/73 213/67 0.447




Age, years, mean ± SD 58.4 ± 21.2 62.2 ± 11.4 0.551





Age, years, mean ± SD 61.3 ± 19.9 62.1 ± 13.5 0.631
Gender, male/female, number 290/150 298/152 0.921
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Despite recent advances in antibiotic therapy and ag-
gressive operative intervention, sepsis remains a difficult
challenge in the ICU that displays a high mortality rate
of 30% to 50% among severe sepsis and septic shock
patients [1-3]. Although the pathophysiological mecha-
nisms underlying sepsis are unclear, pro-inflammatory
cytokines such as IL-6 and IL-1β, which are involved in
the immune response, are clearly closely linked to
the pathogenesis of sepsis [4,5]. Currently, vast evidence
indicates that certain functional genetic variants, such
as those in the genes of TNF-a, IL-6 and other
inflammatory-related proteins, may be associated with
the susceptibility to sepsis by influencing its inflamma-
tory pathogenesis [6-9].
The A disintegrin and metalloproteinase (ADAM) pro-
teins are type I membrane glycoproteins that contain 34
transmembrane domains, as well as a characteristic ex-
tracellular metalloproteinase domain and a disintegrin
domain [10-12]. ADAM10, one member of the ADAM
family, is involved in the shedding of dozens of substrates,
such as CX3CL1, IL-6R, TNF-a and VE-cadherin, and this
process plays a critical role in various inflammation-
related diseases, including Alzheimer’s disease (AD), ath-
erosclerotic cerebral infarction (ACI) and cancer [12-17].
To date, increasing evidence has demonstrated that
ADAM10 affects the production of the inflammatory
cytokines IL-6 and IL-1β in macrophages and thus, is im-
plicated in the process of leukocyte migration and in the
promotion of pro-inflammatory activity [18-20]. Some
studies have revealed that ADAM10 inhibitors performed
beneficial functions, such as increasing apoptosis resis-
tance or suppressing the inflammatory immune response,
in several cell models [21-23]. This evidence suggests that
ADAM10 may play a vital role in the pathogenesis of
directly inflammatory-related diseases, such as sepsis.
The human ADAM10 gene is located on chromosome
15q21.3-q23 and contains 16 exons interrupted by 15
introns [24,25]. Several single-nucleotide polymorphisms
(SNPs) are located in the promoter region of the ADAM10
gene, some of which are functional [26,27]. It has been
reported that the ADAM10 rs514049-rs653765 C-A pro-
moter polymorphisms decrease ADAM10 mRNA expres-
sion in the cerebrospinal fluid of patients with AD [28].
The ADAM10 rs653765 C > T polymorphism, located in
the promoter region, also acts as a functional SNP that in-
fluences ADAM10 mRNA expression [29]. These SNPs are
associated with the susceptibility to several diseases, such
as ACI, AD, conduct disorder and others [29-31].
However, although several studies have suggested a cor-
relation between ADAM10 and sepsis, to date, no study
has examined the association between ADAM10 polymor-
phisms and sepsis. The present case-control study exa-
mined 440 sepsis patients and 450 healthy controls todetermine whether the promoter variations of ADAM10
(rs653765 and rs514049) are associated with susceptibility
to sepsis and whether these two functional SNPs influence
ADAM10 expression in sepsis patients. Moreover, to in-
vestigate the effect of these ADMAM10 variants on the
inflammation process, we analyzed the possible associa-
tions between these polymorphisms and the expression
levels of downstream substrates of ADAM10 and pro-
inflammatory cytokines in sepsis patients.
Methods
Study population
Our study consecutively enrolled 440 sepsis patients and
450 matched healthy controls from two regions of China
between July 2009 and December 2013. This sample in-
cluded 273 sepsis patients from the ICU and 280 healthy
controls from the Health Examination Center of the
Affiliated Hospital of Guangdong Medical College in
southern China (Zhanjiang, China) and 167 sepsis pa-
tients and 170 healthy controls from Harbin Medical
University in northern China (Harbin, China). The blood
samples were collected upon the diagnosis of sepsis. The
sepsis subtypes were defined according to the International
Sepsis Definitions Conference in 2001 [32]. Patients with a
history of malignant tumors, human immunodeficiency
virus, autoimmune diseases, blood diseases, ACI or other
organic diseases were excluded. All participants were
members of the Chinese Han population and were older
than 18 years of age. The participants in the healthy con-
trol group were free from any recent acute illness, any
chronic illness such as autoimmune diseases, hyperten-
sion, diabetes, cancer or major cardiac, renal, hepatic,
endocrinological disorders and any history of sepsis. No
significant differences were observed in age or gender
between the patients and the controls in the two districts
(Table 1). Written informed consent was obtained from
all of the enrolled participants, and this study was
reviewed and approved by the Ethics Committee of
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(Zhanjiang, China) and the Fourth Affiliated Hospital of
Harbin Medical University (Harbin, China).
DNA isolation and genotyping
Genomic DNA was extracted from whole blood using the
TIANamp Blood DNA Kit (TianGen Biotech, Beijing,
China) according to the manufacturer’s instructions. The
purified DNA was quantified in a spectrophotometer and
was stored at −80°C until analysis. A SNaPshot Multiplex
Kit was used to analyze the gene polymorphisms (Genesky
Biotechnologies, Inc., Shanghai, China). Briefly, for
rs653765-rs514049, the forward primer was AGCACC
TCCCTCTCGCTCCAC, and the reverse primer was
TGCATTTATGTTCGCATCACTGG. Polymerase chain
reaction (PCR) was conducted in a final volume of 10 μL,
which contained 5 μL of the SNaPshot Multiplex Kit
reagent (ABI), 2 μL of the templates containing the multi-
plex PCR products, 1 μL of the primer mix and 2 μL of
water. The PCR reaction protocol was as follows: after de-
naturation at 95°C for 2 minutes, 11 cycles of DNA ampli-
fication were performed using Taq PCR for 20 s at 94°C
(denaturation), 40 s at 65°C (annealing), and 90 s at 72°C
(extension), followed by 24 cycles of DNA amplification
for 20 s at 94°C (denaturation), 30 s at 59°C (annealing),
and 90 s at 72°C (extension). The amplified products were
stored at 4°C. The extension products were purified for
1 h at 37°C via incubation in 1 U of shrimp alkaline phos-
phatase (Takara, Otsu, Shiga, Japan), followed by incuba-
tion for 15 minutes at 75°C to inactivate this enzyme.
Additionally, 0.5 μL of the purified products was mixed
with 9 μL of Hi-Di formamide and 0.5 μL of Liz120 Size
Standard. Next, the samples were incubated for 5 minutes
at 95°C and then inserted into the ABI Prism 3130XL
genetic sequence analyzer. All individuals were success-
fully genotyped for the SNPs rs653765 and rs514049. In
addition, 10% of the samples were randomly selected as
the validation group for re-genotyping. The final data were
analyzed using GeneMapper 4.1 (Applied Biosystems,
Foster City, CA, USA).
Mononuclear cell isolation and ELISA
We randomly selected 76 patients with sepsis and 84
healthy controls from the recruited individuals for the
isolation of mononuclear cells. The 76 sepsis samples in-
cluded 7 samples of sepsis, 49 samples of severe sepsis
and 20 samples of septic shock. The genotype distribu-
tion of the rs653765 polymorphism in the severe sepsis
patients was as follows: 36 patients carrying the CC
genotype and 13 patients carrying the CT/TT genotype.
The genotype distribution of rs514049 polymorphism
was 44 patients carrying the AA genotype and 5 patients
carrying the AC/CC genotype. Moreover, 64 and 22
healthy controls carried the CC and CT/TT genotypes ofrs653765, respectively, and 74 and 10 healthy controls
carried the AA and AC/CC genotypes of rs653765,
respectively; these healthy controls were selected as
the control group. Peripheral blood mononuclear cells
(PBMCs) were isolated from 10 mL of peripheral blood
by the density gradient centrifugation method using
Lymphoprep™ (Axis-Shield PoCAS, Oslo, Norway). In
short, an equal volume of 0.9% NaCl was added to the
blood samples, and the diluted blood was layered above
a Ficoll-Paque PREMIUM solution. Then, the samples
were centrifuged at 800 × g for 30 minutes at room
temperature, which caused the mononuclear cells to
form a distinct band at the media interface. Subse-
quently, we transferred the cells to fresh tubes using
Pasteur pipettes without removing the upper layer and
then washed these cells with 0.9% NaCl. Finally, we cen-
trifuged the samples again at 250 × g for 10 minutes, and
the mononuclear cells that we obtained were stored
at −80°C. ELISA was performed according to the manu-
facturer’s instructions to measure the levels of substrates
and inflammatory cytokines in the supernatants of the
isolated PBMCs. CX3CL1, TNF-α, IL-6R, IL-6 and IL-1β
were measured in the PBMCs using each specific ELISA
kit (R&D Systems, Minneapolis, MN, USA). Then, the
absorbance of each sample was determined at 450 nm
using a microplate reader, and the final cytokine levels
were analyzed according to a standard curve. The mini-
mum detectable levels of IL-1β, TNF-α, IL-6, IL-6R and
CX3CL1 were 5 pg/mL, 8 pg/mL, 2 ng/L, 15 ng/L and
0.3 ng/mL, respectively.
RNA extraction and real-time PCR
Total cellular RNA was extracted as soon as possible
after the isolation of the mononuclear cells using the
RNAprep Pure Blood Kit (Sangon Biotech, Shanghai,
China) according to the manufacturer’s instructions. The
RNA samples were assessed via agarose gel electropho-
resis and were stored at −80°C. Then, equal amounts
(5 μL) of total RNA were reverse-transcribed using a
First Strand cDNA Synthesis Kit (Thermo Fisher Scientific,
Waltham, MA, USA) according to the manufacturer’s
instructions. The mRNA expression level of ADAM10
was determined via real time (RT)-PCR using the SYBR
green method. The primers used in this assay were as
follows: ADAM10 sense primer, CTGGCCAACCTATTT
GTGGAA, and antisense primer, GACCTTGACTTG-
GACTGCACTG; GAPDH sense primer, GAAGGGCTC
ATGACCACAGTCCAT, and antisense primer, TCATT
GTCGTACCAGGAAATGAGCTT. All measurements
of ADAM10 were performed in triplicate. Briefly, the
ADAM10-specific primers were diluted to a final
concentration of 1 μM, and the final volume of 10 μL
of the PCR amplification reaction was mixed with 5 μL
of 2 × SYBR Green PCR master mix (TaKaRa), 0.2 μL of
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DNase-free water and 1 μL of cDNA as a template. The
relative level of each transcript normalized to the house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase
was determined. RT-PCR was performed using a Light-
Cycler 480 sequence detector system (Roche Applied
Science, Laval, Quebec, Canada) as follows: initial step of
95°C for 30 s, followed by 40 cycles of 95°C for 5 s and
60°C for 20 s. The relative expression levels of ADAM10
mRNA in all participants were obtained using the 2-△△Ct
method.
Plasmid constructs
Based on our haplotype assay results, three haplotype vari-
ants of the ADAM10 3′UTR (rs514049-rs653765-A-C,
rs514049-rs653765-A-T and rs514049-rs653765-C-T) were
amplified from the promoter of the ADAM10 gene using
PCR. Briefly, the AMA10 promoter gene fragments were
amplified by PCR. The sequences of the primers were as
follows: ADAM10: 5′- CTCGCAGTCGTGCCTCAC and
3′ -AATTCGGCCTACTCAAGCAC. The three ADAM10
promoter haplotypes in our study were amplified by PCR
from the genomic DNA based on the known alleles of
rs514049 and rs653765. Each amplified product was veri-
fied by dissociation curves and gel electrophoresis and was
then cloned into the expression region of the pGL4.10
vector (Promega, Madison, Wisconsin, USA). After trans-
formation into Escherichium coli DH5α cells, all of the
plasmids were isolated and purified using a Plasmid Midi
Kit (Promega, USA). The inserted fragments were confirmed
by sequencing.
Cell culture
The human acute monocytic leukemia cell line THP-1
(Shanghai Institute of Cell Biology, China) was cultured as
cell suspensions in RPMI 1640 medium (HyClone, Logan,
UT, USA) supplemented with 10% heat-inactivated FBS
(Hyclone, USA), 100 U/ml penicillin, and 100 μg/mL
streptomycin (Gibco-BRL, Life Technologies, Grand Island,
NY, USA). The THP-1 cells were maintained at 37°C in a
humidified incubator containing 5% CO2 during growth and
treatment. The cells were subcultured at a split ratio from
1:2 to 1:3 and were passaged every 2 to 3 days. The treat-
ments were administered to a density of 2 × 105 cells/mL in
12-well plates.
Luciferase assay
THP-1 cells were transiently transfected for 48 h with
the firefly luciferase pGL4.10 (luc2) haplotype reporter
and Renilla luciferase pGL4.75 vectors using Lipofecta-
mine 2000 (Invitrogen, USA) according to the manufac-
turer instructions. Three parallel samples were used in
all transfections, and all experiments were performed in
triplicate. The assays were performed according to theprotocol of the dual-luciferase assay kit (Promega, USA).
The luminescence was measured using a Mithras LB940
Multilabel Reader (Berthold Technologies, Bad Wildbad,
Germany). The activity of Renilla luciferase was normal-
ized to that of firefly luciferase.
Statistical analyses
All data were analyzed using SPSS 17.0 and GraphPad
Prism 4.0 (GraphPad Software, Inc., San Diego, CA,
USA). The Benjamin-Hochberg procedure for multiple-
testing correction was used to analyze the false discovery
rate. The genotype and allele frequencies were calculated
using the chi squared or Fisher’s exact test as appropri-
ate. The distributions of the genotype frequencies for
the two SNPs were consistent with Hardy-Weinberg
equilibrium for all participants (Additional file 1: Table S1).
Power analysis was performed using QUANTO 1.2 soft-
ware. Power analysis showed that based on our sample
size, we had 90.1% power for rs653765 and 64.3% power
for rs514049 to detect a relative risk difference between
genotypes at an odds ratio of 1.5 and a significance level
of 0.05. Student’s t-test or the Mann-Whitney U-test
was used for normally distributed and non-parametric
data, respectively. Analysis of variance (ANOVA) was per-
formed for all other calculations. All data are presented as
the mean ± standard error of the mean (SEM). A differ-
ence was considered to be significant at a P-value <0.05.
Results
Clinical characteristics
The characteristics of the study participants are shown
in Tables 1 and 2. In total, 890 participants were re-
cruited in this study, 440 patients with sepsis and 450
healthy controls. No significant differences in age or gen-
der distribution were detected between the cases and the
controls (Table 1). The mean age was 61.31 ± 19.86 years
for the patients with sepsis and 62.07 ± 13.45 years for the
controls. Lung tissue (60.5%), abdominal tissue (16.4%) and
trauma (12.5%) were the primary sources of infection.
Gram-negative infection (32.0%), fungi (20.7%) and poly-
microbial infection (16.6%) were the primary pathogens.
Acinetobacter baumannii (25.9%, 7.5% were single bacterial
strains), yeast sporophytes and Aspergillus (8.9%) were the
primary pathogenic bacteria. The dysfunction of two or
more organs was observed in 84.5% of the total patients.
The percentages of patients with sepsis, severe sepsis and
septic shock were 15.5%, 62.9% and 21.6%, respectively
(data not shown). The 28-day mortality rate was 17.5% in
this study cohort (Table 2).
Association of ADAM10 polymorphisms with sepsis
susceptibility
The genotype and allele frequencies of the ADAM10
SNPs for the cases and the controls are presented in
Table 2 Epidemiologic data of sepsis patients
Variable Sepsis group
(n = 440)
Age, years, mean ± standard error of the mean 61.31 ± 19.86
Male/female, number 290/150
Primary diagnosis (%) 51 (11.6)
Previous health status (%)
Previous surgery 55 (12.5)
Hypertension 61 (13.9)









Drainage liquid 7 (1.6)
Others 4 (0.9)
Identified pathogen, n (%)
Gram-positive 46 (10.5)
Gram-negative 141 (32.0)
Mix of gram-positive and gram-negative 46 (10.5)
Fungus 91 (20.7)
Polymicrobial 73 (16.6)
Negative blood culture 46 (10.5)
Pathogenic bacteria
Acinetobacter baumannii 114 (25.9)
Yeast sample sporphyte 39 (8.9)
Aspergillus 20 (4.5)
Pseudomonas aeruginosa 22 (5.0)
Staphylococcus aureus 20 (4.5)
Staphylococcus haemolyticus 16 (3.6)
Escherichia coli 13 (3.0)
Others 83 (18.9)
Number of organs with dysfunction (%)
1 68 (15.5)
2 140 (31.8)
3 or more 232 (52.7)
APACHE II score, mean ± standard error of the mean 26.17 ± 6.13
28-day mortality, % 77 (17.5)
Results are presented as number (%) unless stated otherwise. APACHE, acute
physiology and chronic health evaluation.
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ference in any genotype or allele frequency was observed
between the sepsis patients and the controls, suggestingthat the ADAM10 SNPs may not affect the risk of sepsis.
When dividing the cases into the subtypes of sepsis,
severe sepsis and septic shock, our results revealed a sig-
nificant difference in the genotype and allele frequencies
of the rs653765 SNP between the sepsis and severe sepsis
subtypes (P = 0.0014) or between the severe sepsis and
septic shock subtypes (P = 0.0037) (Table 4). The C allele
and the CC genotype of rs653765 displayed a trend to-
ward promoting the development of sepsis. With regard
to the other SNP, the AA genotype and the A allele of the
rs514049 SNP displayed a significant difference between
the septic shock and sepsis subtypes but not between the
sepsis and severe sepsis subtypes (P = 0.428) or between
the severe sepsis and septic shock subtypes (P = 0.210)
(Table 4). Moreover, the frequencies of the haplotypes of
the ADAM10 SNPs in the sepsis patients and the healthy
controls were analyzed using Haploview software, but no
significant differences were detected (Table 5).
Influence of these ADAM10 polymorphisms on the
expression levels of ADAM10
The difference in the ADAM10 mRNA expression level
between each genotype was further analyzed in the
sepsis patients. As shown in Figure 1A, we found that
the sepsis patients displayed a significantly higher
ADAM10 mRNA expression level than the healthy
controls (Figure 1A, P <0.01). When the sepsis patients
were divided into subgroups, we observed that ADAM10
expression was significantly higher in the patients with
severe sepsis or septic shock than in the patients with
sepsis (Figure 1B, both P <0.01). Next, we analyzed the
genotype distribution of ADAM10 mRNA expression to
investigate the possible relationship between these poly-
morphisms and the expression of the ADAM10 gene in
severe sepsis patients. As shown in Figure 1C, the rs653765
CC carriers exhibited significantly higher ADAM10 mRNA
expression levels than the patients who carried the CT or
TT genotype (P <0.05), whereas the healthy patients who
carried the same polymorphic alleles displayed no sig-
nificant difference (Figure 1C). For the rs514049 poly-
morphism, no significant differences in the ADAM10
expression levels were observed in the genotypes between
the cases or the controls (Figure 1D). Furthermore, we
performed luciferase assays using the THP-1 cell line to
characterize the rs514049-rs653765 ADAM10 promoter
haplotypes and found that the ADAM10 C-A haplotype
carriers displayed significantly higher reporter activity
than the T-A carriers and the T-C carriers (Figure 1E),
suggesting that the C allele of rs653765 may the primary
factor that increases ADAM10 expression in THP-1 cells.
These results are consistent with our previous case-
control results, suggesting that rs653765 is a functional
SNP that may be involved in the pathology of sepsis via
the regulation of ADAM10 mRNA expression.
Table 3 Frequency distribution of rs653765 and rs514049 genotypes and alleles in sepsis patients and healthy controls
Cases (n = 440) (%) Controls (n = 450) (%) P P* Adjusted odds ratio (95% CI)
rs653765 C > T
CC 346 (78.6) 338 (75.1) 0.234 0.234 -
CT 82 (18.6) 91 (20.2) - - -
TT 12 (2.7) 21 (4.7) - - -
CC/CT 428 (97.3) 429 (95.3) 0.126 0.234 1.746 (0.848, 3.594)
TT/CT 94 (21.4) 112 (24.9) 0.213 0.234 0.820 (0.600, 1.121)
C 774 (88.0) 767 (85.2) - - 1.000 (reference)
T 106 (12.0) 133 (14.8) 0.091 0.234 0.790 (0.600, 1.039)
rs514049 A > C
AA 388 (88.2) 394 (87.6) 0.954 1.000 -
AC 48 (10.9) 52 (11.6) - - -
CC 4 (0.9) 4 (0.9) - - -
AA/AC 436 (99.1) 446 (99.1) 1.000 1.000 0.978 (0.243, 3.935)
AC/CC 52 (11.8) 56 (12.4) 0.775 1.000 0.943 (0.630, 1.411)
A 824 (93.6) 840 (93.3) 1.000 (reference)
C 56 (6.4) 60 (6.7) 0.796 1.000 0.952 (0.653, 1.387)
*False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamin-Hochberg method.
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the expression levels of related cytokines
The differences in the expression levels of ADAM10
substrates (CX3CL1, IL-6R and TNF-a) and the pro-
inflammatory cytokines IL-1ß and IL-6 according to the
ADAM10 genotype were analyzed in PBMCs from the
sepsis patients and the controls. Our results indicated
that the expression of CX3CL1, IL-6R, TNF-a, IL-1ß and
IL-6 were significantly higher in the sepsis patients (sub-
type) than in the healthy controls (Figure 2A-D). Among
the three patient subgroups, the severe sepsis patients dis-
played the highest CX3CL1 expression level (Figure 2F),
whereas the sepsis subtype patients displayed the lowestTable 4 Frequency distribution of rs653765 and rs514049 gen
Sepsis subtype Severe sepsis Septic shock Severe sep
(n = 55) (%) (n = 288) (%) (n = 97) (%) (n = 385) (%
rs653765 C > T
CC 35 (63.6) 238 (82.6) 73 (75.3) 311 (80.8)
CT/TT 20 (36.4) 50 (17.4) 24 (24.7) 74 (19.2)
C 87 (79.1) 520 (90.3) 167 (86.1) 687 (89.2)
T 23 (20.9) 56 (9.7) 27 (13.9) 83 (10.8)
rs514049 A > C
AA 45 (81.8) 252 (87.5) 91 (93.8) 343 (89.1)
AC/CC 10 (18.2) 36 (12.5) 6 (6.2) 42 (10.9)
A 100 (90.9) 536 (93.1) 188 (96.9) 724 (94.0)
C 10 (9.1) 40 (6.9) 6 (3.1) 46 (6.0)
P1, sepsis group versus severe sepsis; P2, sepsis group versus septic shock; P3, seps
P-value for multiple hypotheses testing using the Benjamin-Hochberg method.expression of TNF-a, IL-6 and IL-1β (Figure 2H-J). How-
ever, no significant differences in IL-6R expression were
observed between the subgroups (Figure 2G). Next, we
analyzed the differences in these cytokines according to
the ADAM10 genotype. Our results revealed that the
ADAM10 rs653765 CC genotype carriers exhibited a sig-
nificant increase in the expression of the three substrates
of ADAM10 (CX3CL1, IL-6R and TNF-a) compared with
the rs653765 CT/TT carriers in the subgroup of severe
sepsis patients (Figure 3A-C) but that the expression levels
of the pro-inflammatory cytokines IL-1β and IL-6 were
not significantly associated with the rs653765 poly-
morphism (Figure 3D,E). In addition, no significantotypes and alleles between sepsis subtypes
sis/septic shock P1 P2 P3 P1* P2* P3*
)
0.0014 0.129 0.0037 0.0014 0.129 0.0037
- - - - - -
0.0008 0.114 0.0023 0.0014 0.129 0.0037
- - - - - -
0.257 0.021 0.118 0.428 0.024 0.210
- - - - - -
0.428 0.024 0.210 0.428 0.024 0.210
- - - - - -
is group versus severe sepsis/septic shock. *False discovery rate-adjusted
Table 5 Frequencies of haplotypes of the ADAM10 gene in sepsis patients and controls
rs514049-rs653765 Cases, n (%) Controls, n (%) P P* Odds ratio (95% CI)
A-C 786 (89.3) 781 (86.8) - - 1.000 (reference)
A-T 49 (5.6) 60 (6.7) 0.293 0.293 0.812 (0.549, 1.199)
C-T 45 (5.1) 59 (6.6) 0.174 0.293 0.758 (0.508, 1.131)
Values were adjusted for age and sex. *False discovery rate-adjusted P-value for multiple hypotheses testing using the Benjamin-Hochberg method.
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morphisms and the sepsis-related substrates that we
measured in our study (Figure 3F-J).
Discussion
Increasing evidence has demonstrated that ADAM10 is
intimately linked to inflammation and may mediate
inflammation-related biological and pathological proces-
ses [33-35]. A recent study reported that ADAM10 in-
duces the loss of endothelial barrier function in septic
mice and that the severity of cellular injury and sepsis is
mitigated by ADAM10 inhibition [22], which led us to
investigate the relationship between ADAM10 and sep-
sis. To the best of our knowledge, our study is the first
to investigate the association between two functionalFigure 1 Expression levels of A disintegrin and metalloproteinase 10 (A
Expression levels of ADAM10 in sepsis patients and healthy controls (A). E
subgroup (B); the genotype distribution between the rs653765 polymorp
distribution between the rs514049 polymorphisms and the expression of
haplotypes on transcriptional activity of ADAM10. In luciferase assays in TH
(E); the horizontal line represents the mean expression level of ADAM10 wpolymorphisms (rs653765 and rs514049) in the ADAM10
gene and the risk of sepsis. No statistically significant dif-
ferences between sepsis cases and controls in the genotype
or allele frequencies were observed, suggesting that the
ADAM10 SNPs may not be the risk factor for the occur-
rence of sepsis. The novel findings from a secondary ana-
lysis were that the rs653765 C allele and CC genotype of
rs653765 displayed a trend toward promoting the deve-
lopment of sepsis from the sepsis to severe sepsis subtype,
and the CC genotype carriers was associated with higher
ADAM10 mRNA expression in the severe sepsis subtype
than in the sepsis (subtype) and further influenced the ex-
pression of ADAM10 substrates in the severe sepsis sub-
type, thereby potentially contributing to the progression
from sepsis to severe sepsis.DAM10) polymorphisms in sepsis patients and healthy controls.
xpression levels of ADAM10 in sepsis, severe sepsis and septic shock
hisms and the expression of the ADAM10 gene (C); the genotype
the ADAM10 gene in severe sepsis (D); effect of rs514049-rs653765
P-1 cells, luciferase activity was presented as a ratio (Firefly/Renilla)
ith each group. *P <0.05; **P <0.01; ***P <0.001.
Figure 2 Expression levels of CX3CL1 (A), IL-6R (B), TNF-α (C), IL-6 (D) and IL-1β (E) between the sepsis patients and healthy controls,
and expression levels of CX3CL1 (F), IL-6R (G), TNF-α (H), IL-6(I) and IL-1β (J) in the sepsis, severe sepsis and septic shock subgroups.
The horizontal line represents the mean expression level of ADAM10 with each group. *P <0.05; **P <0.01; ***P <0.001.
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ADAM10 SNPs affect mRNA expression and are involved
in various inflammation-related diseases [28,29]. A recent
study has shown that nucleotides −2179 to −1 of the
ADAM10 gene represent functional TATA-less promoters
[24]. Bekris et al. discovered that the ADAM10 rs514049-
rs653765 C-A promoter haplotype, especially the rs514049
C allele, is associated with a higher cerebral spinal fluid
sAPPa level in cognitively normal controls than in patients
with AD [28]. Another previous study showed that the
rs653765 C > T polymorphism is located downstream of
the potential binding site for the myc-associated zinc
finger protein transcription factor, suggesting that the
rs653765 polymorphism may be a functional SNP [24]. In
addition, Li et al. demonstrated a positive associationFigure 3 The genotype distribution between the rs653765 polymorph
(D) and IL-1β (E) in severe sepsis patients and controls, and genotype
expression of CX3CL1 (F), IL-6R (G), TNF-α (H), IL-6(I) and IL-1β (J) in s
the mean expression level of ADAM10 with each group. *P <0.05; **P <0.01between the ADAM10 polymorphism rs653765 and ACI
risk [29]. Consequently, in the present study, we in-
vestigated the association of these two functional SNPs,
rs514049 and rs653765, which are located in the promoter
region of the ADAM10 gene, with the risk of sepsis. Our
initial results did not reveal a significant difference be-
tween the sepsis patients and the healthy controls, suggest-
ing that these SNPs may not be related to the occurrence
of sepsis. However, when we divided the sepsis sample into
subgroups according to the severity of sepsis, we found
that the C allele and the CC genotype of the rs653765
SNP resulted in a higher risk for the severe sepsis subtype
than for the sepsis subtype. Moreover, among the patients
with severe sepsis, the rs653765 CC genotype carriers
exhibited a higher ADAM10 expression level than theisms and the expression of CX3CL1 (A), IL-6R (B), TNF-α (C), IL-6
distribution between the rs514049 polymorphisms and the
evere sepsis patients and controls. The horizontal line represents
; ***P <0.001.
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be functional. To further confirm this result, we perform a
luciferase activity assay using the THP-1 cell line con-
sisting of three rs514049 – rs653765 ADAM10 promoter
haplotypes to determine which haplotype exerts an effect
on the expression of ADAM10 expression. The C-A vari-
ants displayed a higher level of luciferase activity than the
T-A and T-C variants in the THP-1 cells, suggesting that
rs653765 may be a functional SNP and that the C allele
may increase the expression of ADAM10. Furthermore,
we found that the ADAM10 expression level in the sepsis
subgroups was consistent with the results of our case-
control study and that the healthy controls did not display
altered ADAM10 expression or the differential expression
of ADAM10 between the different genotypes. These
results indicated that ADAM10 may influence the progres-
sion of sepsis rather than the occurrence of sepsis. How-
ever, another SNP of the ADAM10 gene, the rs514049
A > C polymorphism, which has been reported to perform
a similar function to the rs653765 SNP, was not signifi-
cantly associated with the expression of ADAM10 in our
study. We speculate that this result could be attributed to
the binding of different promoters to distinct regions of
these SNPs. Our subsequent study will focus on the
molecular mechanisms underlying these two functional
SNPs utilizing a promoter prediction method and the ex-
perimental confirmation of our results in a cellular model
of sepsis.
We further detected the downstream substrates of
ADAM10 in PBMCs and attempted to determine whether
the ADAM10 polymorphism further affects the expression
levels of its substrates. CX3CL1 induces the detachment of
monocytes and guides leukocytes to the site of inflamma-
tion, and ADAM10 is the major protease involved in the
release of CX3CL1 under pro-inflammatory conditions
[36-38]. IL-6R is primarily generated via ADAM10-
mediated ectodomain shedding, and inducing IL-6 trans-
signaling leads to inflammatory processes [39-41]. In
addition to its role as a pro-inflammatory cytokine, recent
studies have indicated that ADAM10 may also function as
a sheddase of TNF-α in cells [41,42]. Therefore, three
representative ADAM10 substrates, CX3CL1, IL-6R and
TNF-a, were selected for analysis in this study. We found
that the severe sepsis patients expressed significantly
higher levels of CX3CL1, IL-6R, and TNF-a than the
healthy controls. Importantly, we found that among the
subgroup of patients with severe sepsis, the rs653765 CC
genotype carriers expressed significantly higher levels of
CX3CL1, IL-6R and TNF-a than the CT/TT carriers. This
finding is consistent with our previous results describing
the association between the rs653765 polymorphism and
the risk of severe sepsis and supports the hypothesis that
the ADAM10 rs653765 CC genotype contributes to the
pathogenesis of severe sepsis by increasing the ADAM10mRNA expression level, accompanied by the upregulation
of its substrates.
Evidence indicates that ADAM10 is involved in the
development and progression of inflammation via vari-
ous cellular processes. For instance, ADAM10 induces
the secretion of IL-1β and IL-6 in macrophages by acti-
vating the extracellular signal-regulated kinase 1/2 and
NF-κB signaling pathways [43]. In addition, ADAM10-
Dll4 signaling represents a major signaling pathway in
human endothelial cells that drives the inflammatory
events involved in the release of IL-6 [44]. Furthermore,
both the ADAM10 inhibitor GI254023X and ADAM10
siRNA block the inflammatory process by decreasing
vascular permeability and the expression levels of pro-
inflammatory cytokines [22,23]. To determine whether
this functional ADAM10 SNP ultimately influences the
expression of pro-inflammatory cytokines, we investi-
gated the expression levels of IL-1ß and IL-6 in PBMCs
from patients with severe sepsis. We found that the
patients with sepsis expressed significantly higher IL-1ß
and IL-6 levels than the healthy controls, as predicted.
Nevertheless, no significant associations were observed
between the ADAM10 polymorphisms and these pro-
inflammatory cytokines in the severe sepsis patients. We
speculate that several reasons may contribute to this
result. Because the inflammatory system is vast and
complex, the increase in the ADAM10 mRNA level
attributable to the rs653765 CC genotype may not be
sufficiently strong to significantly influence inflammatory
signaling during the development of severe sepsis.
Alternatively, ADAM10 may ultimately influence the
risk of severe sepsis via other inflammation- or non-
inflammation-related pathways aside from those which
we examined. In contrast, it is difficult to achieve strict
homogeneity under the ever-changing pathogenic condi-
tions of the sepsis patients in this study, which may have
contributed to this negative result. Nevertheless, further
investigation is required to confirm these results.
Furthermore, the allele frequencies of the ADAM10
polymorphisms differ in distinct healthy populations. In
the Chinese Han population examined in our study, the
rs653765 allele frequency was 85.2% for the C allele, and
the rs514049 allele frequency was 93.3% for the A allele;
these allele frequencies are similar to previous data in
Chinese individuals (86.5% for the rs653765 C allele and
94.3% for the rs514049 A allele) [29], whereas another
study of white individuals showed that the rs653765 C
allele frequency was 24.1% and that the rs514049 A
allele frequency was 39.8% [45], which are far lower than
the frequencies observed in the Han Chinese popula-
tions. Ethnic differences may contribute to this diversity.
Notably, the associations between the two functional
SNPs of ADAM10 and disease have been reported in
only three articles to date [28,29,45]. Further studies of
Cui et al. Critical Care  (2015) 19:73 Page 10 of 11these polymorphisms using larger sample sizes and in
different ethnicities should be conducted.
Some potential limitations in our study should be ad-
dressed. For now no study about the association between
these ADAM10 SNPs and sepsis has been reported in
other population, and we still need the validation cohort
study for further confirm our results, further investiga-
tion with a larger and more ethnically diverse population
of septic patients is warranted to support our prelimi-
nary conclusions. Moreover, although the recruited sep-
tic patients who have certain diseases were excluded in
our study for the homogeneity of samples, there is also a
possibility that ADAM10 genotype were inversely asso-
ciated with diseases that were excluded.
Conclusion
In the present study, for the first time, we demonstrated
that individuals carrying the functional variant rs653765
in the promoter region of ADAM10 may exhibit suscep-
tibility to the development of sepsis. Rs653765 SNP is a
functional SNP in severe sepsis, and the CC genotype
may increase the ADAM10 mRNA expression level,
thereby influencing the levels of ADAM10 substrates,
which may ultimately contribute to the risk for the
development of sepsis. However, we did not observe any
association between the ADAM10 polymorphisms and
the levels of pro-inflammatory cytokines in the severe
sepsis patients. Future studies will focus on the mecha-
nisms by which this functional SNP (rs653765) is in-
volved in the pathogenesis of sepsis.
Key messages
 For the first time exploring the relationship between
ADAM10 polymorphisms and sepsis.
 Individuals with a functional variant (rs653765) in
the promoter region of ADAM10 may have
susceptibility to the development of sepsis
 The risk CC genotype of rs653765 could
functionally affect the expression level of ADAM10
mRNA and accompanied with the upregulation of
the expression levels of its substrates in severe sepsis
 This risk polymorphism may confer the
susceptibility to the development of sepsis more
than through inflammatory pathways
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